Back to Results
First PageMeta Content
Law / Organofluorides / Intellectual property law / Patent law of the European Union / Supplementary protection certificate / European Patent Organisation / Abacavir / European Patent Convention / ViiV Healthcare / Chemistry / Organic chemistry / Cyclopropanes


PIPELINE WATCH Abacavir arrives at European SPC expiries he end of June 2014 will bring the end of supplementary protection certificate (SPC) exclusivity for the antiretroviral abacavir throughout western Europe, as wel
Add to Reading List

Document Date: 2014-07-30 02:15:45

Open Document

File Size: 755,80 KB

Share Result on Facebook

Company

Lundbeck / Bayer / Merck KGaA / Pfizer / GlaxoSmithKline / Teva / Novo Nordisk / /

Continent

North America / Europe / /

Country

Switzerland / Germany / Romania / Hungary / Netherlands / Italy / Sweden / Latvia / Norway / Belgium / France / United States / Portugal / United Kingdom / Luxembourg / Finland / Spain / Greece / Ireland / Denmark / Czech Republic / /

Currency

GBP / USD / /

/

Event

Business Partnership / /

Facility

PIPELINE WATCH Abacavir / /

IndustryTerm

diabetes treatment / /

MedicalCondition

pseudomonas / urge incontinence / head and neck cancer / specific infections / Novo Nordisk’s Levemir diabetes / /

Organization

Switzerland European Union Turkey / Switzerland European Union Canada / Turkey European Union / Ark Patent Intelligence / Patent Intelligence / European Union Australia / European Union / /

Person

Reddy / /

/

Product

zidovudine / Trizivir / Escitalopram / Levemir / Avelox / Ziagen / Cipralex / Epzicom / Estradiol / Abacavir / Abilify / lamivudine / Erbitux / /

PublishedMedium

Molecules / /

Region

western Europe / /

URL

www.arkpatentintelligence.com / /

SocialTag